ArticleFrontiers in neuroscience2026
Synaptic micromechanics and brain softening as a mechanobiological hypothesis for Alzheimer's disease.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is usually framed as a proteinopathy and network disorder, but this view may be incomplete. We propose a mechanobiological hypothesis in which synaptic micromechanics, regional brain softening, vascular pulsatility, and glymphatic transport are parts of a coupled fluid-solid system whose failure contributes to AD progression. In this framework, early synaptic and glial mechanical fragility reduces the capacity of vulnerable circuits to maintain stable structure, efficient signaling, and waste clearance, while age-related tissue softening and impaired perivascular transport amplify amyloid and tau accumulation, network dysfunction, and cognitive decline. This framework integrates converging evidence from dendritic spine to glymphatic system biology, concordant results obtained with diffusion MRI and magnetic resonance elastography, and treats altered tissue mechanics not merely as a correlate of degeneration but as a potentially active multicomponent of disease expression. It further predicts that biomechanical alterations should be detectable before gross atrophy, should covary with glymphatic impairment, and may help explain why molecular pathology and clinical symptoms are often only partly aligned. By positioning brain mechanics as an interface between protein aggregation, synaptic dysfunction, and impaired clearance, this framework identifies testable imaging biomarkers and suggests potential early-stage intervention strategies aimed at preserving tissue resilience as well as reducing pathological protein burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.